Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Multiple Myeloma

Since proteasome inhibition is a common therapeutic strategy in multiple myeloma (MM), scientists investigated Rpn10, a subunit of the 19S proteasome unit, and found that it is highly expressed in MM cells versus normal plasma cells.